Comparison of presenting features and three-year disease course in Turkish patients with Behçet uveitis who presented in the early 1990s and the early 2000s

Ocul Immunol Inflamm. 2012 Dec;20(6):423-8. doi: 10.3109/09273948.2012.713159. Epub 2012 Nov 19.

Abstract

Purpose: To compare Behçet uveitis patients who presented in the 1990s and 2000s.

Methods: Records of 170 patients seen in 1990-1994 and 258 patients seen in 2000-2004 were reviewed. Presenting features were analyzed in the whole cohort. Uveitis attacks, vision, complications, and immunomodulatory treatment (IMT) were compared in patients with 3-year follow-up.

Results: Posterior segment involvement was less common, visual acuity was better, and more patients received IMT before referral in the 2000s. Follow-up revealed no significant difference in number of uveitis attacks in the first 3 years. Less eyes lost useful vision, no patient became legally blind, and fewer severe ocular complications occurred in the 2000s. IMT was started within 3 months in more patients and interferon alfa-2a was used only in the latter study period.

Conclusions: The findings suggest a milder disease at referral, lower rate of severe complications, and a better 3-year visual outcome in patients who presented in the early 2000s.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Behcet Syndrome / complications*
  • Behcet Syndrome / drug therapy
  • Behcet Syndrome / epidemiology
  • Child
  • Disease Progression
  • Female
  • Follow-Up Studies
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Incidence
  • Interferon alpha-2
  • Interferon-alpha / therapeutic use*
  • Male
  • Middle Aged
  • Prognosis
  • Recombinant Proteins / therapeutic use
  • Retrospective Studies
  • Time Factors
  • Turkey / epidemiology
  • Uveitis / drug therapy
  • Uveitis / epidemiology
  • Uveitis / etiology*
  • Visual Acuity*
  • Young Adult

Substances

  • Immunosuppressive Agents
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins